Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Multiple Myeloma 26Neoplasms, Plasma Cell 20Lymphoma 16Neuroblastoma 12Neoplasm Metastasis 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Acute 7Sarcoma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Leukemia 6Colorectal Neoplasms 6Rectal Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Immunoblastic 5Colonic Neoplasms 5Liver Neoplasms 4Immunoglobulin Light-chain Amyloidosis 4Hodgkin Disease 4Burkitt Lymphoma 4Recurrence 3Neuroectodermal Tumors, Primitive, Peripheral 3Neoplasms 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hyperthermia 3Hematologic Neoplasms 3

Interventions

montanide ISA 51 1Tumor Necrosis Factor-alpha 1Melphalan 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Muscle Neoplasms × Melphalan × Clear all
NCT00019968 2023-10-31

Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
Sarcoma

Neoplasms, Sarcoma, Muscle Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡